Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration.
Identifieur interne : 000164 ( Ncbi/Merge ); précédent : 000163; suivant : 000165Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration.
Auteurs : G. Ebersbach [Autriche] ; M. Stöck ; J. Müller ; G. Wenning ; J. Wissel ; Werner Poewe [Autriche]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1999.
English descriptors
- KwdEn :
- Administration, Cutaneous, Adult, Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Corpus Striatum (drug effects), Corpus Striatum (physiology), Cross-Over Studies, Dopamine (physiology), Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Motor Skills (drug effects), Motor Skills (physiology), Neural Inhibition (drug effects), Neural Inhibition (physiology), Nicotine (administration & dosage), Nicotine (adverse effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Substantia Nigra (drug effects), Substantia Nigra (physiopathology).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Nicotine.
- chemical , adverse effects : Antiparkinson Agents, Nicotine.
- drug effects : Corpus Striatum, Motor Skills, Neural Inhibition, Substantia Nigra.
- drug therapy : Parkinson Disease.
- physiology : Corpus Striatum, Dopamine, Motor Skills, Neural Inhibition.
- physiopathology : Parkinson Disease, Substantia Nigra.
- Administration, Cutaneous, Adult, Aged, Cross-Over Studies, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged.
Abstract
Nicotine has been reported to have positive effects on motor performance in patients with Parkinson's disease. In this study, motor performance was evaluated in 16 patients with idiopathic Parkinson's disease during a practical off-period using the motor part of the Unified Parkinson's Disease Rating Scale after 12 hours' exposure to a transdermal patch containing 35 mg nicotine or placebo. The study was performed using a double-blind crossover design. In contrast to previous reports, nicotine exposure was followed by a worsening of symptoms compared with placebo. A negative response to subthreshold dopaminergic stimulation, resulting from an inhibitory effect of low striatal dopamine concentrations acting on a subset of dopamine receptors, might possibly account for this finding.
PubMed: 10584678
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004087
- to stream PubMed, to step Curation: 004087
- to stream PubMed, to step Checkpoint: 004069
Links to Exploration step
pubmed:10584678Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration.</title><author><name sortKey="Ebersbach, G" sort="Ebersbach, G" uniqKey="Ebersbach G" first="G" last="Ebersbach">G. Ebersbach</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Clinic Innsbruck, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Clinic Innsbruck</wicri:regionArea><wicri:noRegion>University Clinic Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Stock, M" sort="Stock, M" uniqKey="Stock M" first="M" last="Stöck">M. Stöck</name></author><author><name sortKey="Muller, J" sort="Muller, J" uniqKey="Muller J" first="J" last="Müller">J. Müller</name></author><author><name sortKey="Wenning, G" sort="Wenning, G" uniqKey="Wenning G" first="G" last="Wenning">G. Wenning</name></author><author><name sortKey="Wissel, J" sort="Wissel, J" uniqKey="Wissel J" first="J" last="Wissel">J. Wissel</name></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10584678</idno><idno type="pmid">10584678</idno><idno type="wicri:Area/PubMed/Corpus">004087</idno><idno type="wicri:Area/PubMed/Curation">004087</idno><idno type="wicri:Area/PubMed/Checkpoint">004069</idno><idno type="wicri:Area/Ncbi/Merge">000164</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration.</title><author><name sortKey="Ebersbach, G" sort="Ebersbach, G" uniqKey="Ebersbach G" first="G" last="Ebersbach">G. Ebersbach</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Clinic Innsbruck, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Clinic Innsbruck</wicri:regionArea><wicri:noRegion>University Clinic Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Stock, M" sort="Stock, M" uniqKey="Stock M" first="M" last="Stöck">M. Stöck</name></author><author><name sortKey="Muller, J" sort="Muller, J" uniqKey="Muller J" first="J" last="Müller">J. Müller</name></author><author><name sortKey="Wenning, G" sort="Wenning, G" uniqKey="Wenning G" first="G" last="Wenning">G. Wenning</name></author><author><name sortKey="Wissel, J" sort="Wissel, J" uniqKey="Wissel J" first="J" last="Wissel">J. Wissel</name></author><author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (physiology)</term><term>Cross-Over Studies</term><term>Dopamine (physiology)</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Motor Skills (physiology)</term><term>Neural Inhibition (drug effects)</term><term>Neural Inhibition (physiology)</term><term>Nicotine (administration & dosage)</term><term>Nicotine (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Nicotine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Nicotine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Motor Skills</term><term>Neural Inhibition</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Corpus Striatum</term><term>Dopamine</term><term>Motor Skills</term><term>Neural Inhibition</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Aged</term><term>Cross-Over Studies</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Nicotine has been reported to have positive effects on motor performance in patients with Parkinson's disease. In this study, motor performance was evaluated in 16 patients with idiopathic Parkinson's disease during a practical off-period using the motor part of the Unified Parkinson's Disease Rating Scale after 12 hours' exposure to a transdermal patch containing 35 mg nicotine or placebo. The study was performed using a double-blind crossover design. In contrast to previous reports, nicotine exposure was followed by a worsening of symptoms compared with placebo. A negative response to subthreshold dopaminergic stimulation, resulting from an inhibitory effect of low striatal dopamine concentrations acting on a subset of dopamine receptors, might possibly account for this finding.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">10584678</PMID><DateCreated><Year>2000</Year><Month>01</Month><Day>20</Day></DateCreated><DateCompleted><Year>2000</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>1999</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration.</ArticleTitle><Pagination><MedlinePgn>1011-3</MedlinePgn></Pagination><Abstract><AbstractText>Nicotine has been reported to have positive effects on motor performance in patients with Parkinson's disease. In this study, motor performance was evaluated in 16 patients with idiopathic Parkinson's disease during a practical off-period using the motor part of the Unified Parkinson's Disease Rating Scale after 12 hours' exposure to a transdermal patch containing 35 mg nicotine or placebo. The study was performed using a double-blind crossover design. In contrast to previous reports, nicotine exposure was followed by a worsening of symptoms compared with placebo. A negative response to subthreshold dopaminergic stimulation, resulting from an inhibitory effect of low striatal dopamine concentrations acting on a subset of dopamine receptors, might possibly account for this finding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ebersbach</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Clinic Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stöck</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wenning</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wissel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>W</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>54-11-5</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000279">Administration, Cutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009048">Motor Skills</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009433">Neural Inhibition</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009538">Nicotine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>12</Month><Day>10</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>12</Month><Day>10</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10584678</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li></country><region><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><noCountry><name sortKey="Muller, J" sort="Muller, J" uniqKey="Muller J" first="J" last="Müller">J. Müller</name><name sortKey="Stock, M" sort="Stock, M" uniqKey="Stock M" first="M" last="Stöck">M. Stöck</name><name sortKey="Wenning, G" sort="Wenning, G" uniqKey="Wenning G" first="G" last="Wenning">G. Wenning</name><name sortKey="Wissel, J" sort="Wissel, J" uniqKey="Wissel J" first="J" last="Wissel">J. Wissel</name></noCountry><country name="Autriche"><noRegion><name sortKey="Ebersbach, G" sort="Ebersbach, G" uniqKey="Ebersbach G" first="G" last="Ebersbach">G. Ebersbach</name></noRegion><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W" last="Poewe">Werner Poewe</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000164 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000164 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:10584678
|texte= Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10584678" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |